Emily Menendez

GU Oncology Now

Scott Tagawa, MD, MS, FACP, and fellow researchers <a href="https://meetinglibrary.asco.org/embargo/record/219893/abstract" target="_blank" rel="noopener">carried out a phase 1/2 trial</a> investigating the combination of 225Ac-J591 with 177Lu-PSMA-I&amp;T (aka PNT2002). The study&rsquo;s results will be presented at the American Society of Clinical Oncology 2023 Annual Meeting.Eligible patients had progressive metastatic castration-resistant prostate cancer (mCRPC), 2 or more prior androgen receptor pathway inhibitors, prior chemotherapy (or unfit/refuse), and 1 or more lesions with a standardized uptake value greater than liver uptake.A total of 18 patients were treated (6 at each dose level) with 177Lu-PSMA-I&amp;T (6.8 GBq), 225Ac-J591 (30, 35, or 40 KBq/kg), and up to 2 doses of combination testosterone replacement therapy 8 weeks apart, with 177Lu-PSMA SPECT following each dose. Of the total patient group, 3 patients did not receive a second dose due to progressive disease or withdrawal.The patient group had a median age of 70 years (range, 54-86 years) and a median prostate-specific antigen (PSA) level of 54.4 (range, 2.43-96.14). A total of 13 (72%) patients had bone metastases, while 9 (50%) had metastases in the lymph nodes, 2 (11%) in the liver, and 2 (11%) in the lungs.The primary objectives of the study were dose-limiting toxicity (DLT) and a recommendation for phase 2 dosing. Phase 2 will test the proportion of patients obtaining a PSA decline greater than 50% (PSA50). DLT was defined as G4 myelosuppression lasting more than 1 week, grade 2 or higher nonhematologic adverse events (AE), or any grade-attributed AE delaying therapy over 3 weeks. Other end points included progression-free and overall survival, radiographic response rate, safety, circulating tumor cell (CTC) changes, patient-reported outcomes, PSMA imaging, and blood/tissue correlatives.As of submission, 7 patients (39%) remain in the study, including 1 without progression at 16 months and another patient with undetectable PSA at 10 months. Follow-up is ongoing, where 17 (94%) patients have PSA decline, and 9 (50%) patients have a PSA over 50%. Of those with paired CTC counts, 4 of 5 (80%) converted from unfavorable to favorable CTC count, 4 of 8 (50%) from detectable to undetectable, and 1 of 2 (50%) remained undetectable. AEs included neutropenia, thrombocytopenia, anemia, pain flare, xerostomia, nausea, and fatigue.The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress. Efficacy will be tested further in the upcoming phase 2 portion of the study with 225Ac-J591 at 35 KBq/Kg and 177Lu-PSMA I&amp;T at 6.8 GBq.

Dose-Escalation Results of 225Ac-J591 Plus 177Lu-PSMA-I&T

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

Phase 1/2 trial results on the combination of 225Ac-J591 with 177Lu-PSMA-I&T were presented at the American Society of Clinical Oncology 2023 Annual Meeting.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe